Elizabeth Czerepak

Elizabeth Czerepak has had an extensive career in big pharma and biotechnology, and as a venture capital investor. For 18 years at Merck & Co., Hoffmann-La Roche and BASF (Knoll) Pharma she held executive positions in finance, business development and corporate development, serving a primary role in Roche’s $5.4bn acquisition of Syntex and BASF Pharma’s $6.9bn sale to Abbott. Later, as Managing Director and General Partner of the BSHI venture fund at J.P. Morgan and Bear Stearns, she led investments in thirteen biotech companies. Most recently, Elizabeth served as CFO of two public and one private biotech companies.